Barclays Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Equal-Weight rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $44 to $46.
May 23, 2023 | 9:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Equal-Weight rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $44 to $46.
The news of Barclays maintaining an Equal-Weight rating on Blueprint Medicines and raising the price target from $44 to $46 indicates a positive outlook for the stock. This could lead to an increase in investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100